Mizuho Securities Downgrades Spark Therapeutics (ONCE) to Neutral Following Acquisition
Tweet
Share
E-mail
Get Alerts ONCE Hot Sheet
Price: $110.05 --0%
Rating Summary:
5 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Rating Summary:
5 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Join SI Premium – FREE
Mizuho Securities analyst Difei Yang downgraded Spark Therapeutics (NASDAQ: ONCE) from Buy to Neutral with a price target of $114.50.
For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.
Shares of Spark Therapeutics closed at $113.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades L'Oreal SA (OR:FP) (LRLCY) to Sell
- TD Cowen Downgrades Apogee Therapeutics Inc (APGE) to Hold
- JPMorgan Downgrades Metcash Ltd. (MTS:AU) (MHTLY) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
